Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.37 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.36 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.36 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.36 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.36 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394617 | 0.86 | XDH (0.46) | CYP2A6KDM4CXDHSLC22A12SETDB1 | |
| SCHEMBL10589976 | 0.81 | KDM4C (0.37) | CYP2A6KDM4CXDHSLC22A12SETDB1 | |
| SCHEMBL1169569 | 0.81 | CYP2A6 (0.41) | CYP2A6KDM4CXDHSLC22A12SETDB1 | |
| SCHEMBL29740345 | 0.81 | CYP2A6 (0.41) | CYP2A6KDM4CXDHSLC22A12SETDB1 | |
| SCHEMBL286231 | 0.79 | CYP2A6 (0.43) | CYP2A6SETDB1MAP2K1 | |
| SCHEMBL23832237 | 0.78 | CYP11B1 (0.39) | CYP2A6KDM4CSETDB1PTGDR2 | |
| SCHEMBL7433331 | 0.76 | CYP2A6 (0.41) | CYP2A6KDM4CSETDB1EGLN2MAP2K1 | |
| SCHEMBL2154388 | 0.76 | EGLN2 (0.52) | CYP2A6SETDB1EGLN2ABCC9ABCC8 | |
| SCHEMBL11434090 | 0.75 | XDH (0.43) | KDM4CXDHSLC22A12FFAR1ABCC9 | |
| SCHEMBL167162 | 0.75 | CSNK2A1 (0.41) | HSD17B1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2713736-B1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| US-10117875-B2 | Immune system modulators | JANUS BIOTHERAPEUTICS, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| US-20170224699-A1 | NOVEL IMMUNE SYSTEM MODULATORS | Wilmer Cutler Pickering Hale and Dorr LLP | 2017-08-10 | — | — | US | disclosed |
| US-9637489-B2 | Immune system modulators | JANUS BIOTHERAPEUTICS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9359361-B2 | Immune system modulators | JANUS BIOTHERAPEUTICS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160074403-A1 | NOVEL IMMUNE SYSTEM MODULATORS | Wilmer Cutler Pickering Hale and Dorr LLP | 2016-03-17 | — | — | US | disclosed |
| US-9126996-B2 | Immune system modulators | JANUS BIOTHERAPEUTICS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140221646-A1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140079724-A1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| WO-2012167046-A1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| US-8026260-B2 | Histone deacetylase inhibitors with aryl-pyrazolyl-motifs | MERCK SHARP & DOHME CORP. (US) | 2011-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140079724-A1 | NOVEL IMMUNE SYSTEM MODULATORS | HLA-DRB1, CD47, MYD88 | CYP2A6 1124/4885KDM4C 1646/4885XDH 1921/4885 |
| US-20140221646-A1 | NOVEL IMMUNE SYSTEM MODULATORS | HLA-DRB1, CD47, MYD88 | CYP2A6 1124/4885KDM4C 1646/4885XDH 1921/4885 |
| US-10117875-B2 | Immune system modulators | HLA-DRB1, CD47, MYD88 | CYP2A6 636/4885KDM4C 1463/4885XDH 1356/4885 |
| US-20160074403-A1 | NOVEL IMMUNE SYSTEM MODULATORS | HLA-DRB1, CD47, MYD88 | CYP2A6 1124/4885KDM4C 1646/4885XDH 1921/4885 |
| US-20170224699-A1 | NOVEL IMMUNE SYSTEM MODULATORS | HLA-DRB1, CD47, MYD88 | CYP2A6 1124/4885KDM4C 1646/4885XDH 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.